2006•Unpublished venueRequires access

Analyses of expression and function of P-glycoprotein in relapsed/refractory acute myelogenous leukemia patients

Sun Kai-la

Open publisher page 1 citations

Abstract

Objective To study the expression and function of P-glycoprotein in patients of relapsed/refractory acute myelogenous leukemia(AML). Methods CD34 expression was detected by immunohistochemistry, P-gp expression was detected by RT-PCR and P-gp function was analyzed by flow cytometry. Results CD34 expression has positive relevance with P-gp expression and function(r =0.621, P 0.001; r =0.496, P 0.001). P-gp expression has positive relevance with P-gp function (r = 0.574, P 0.01); positive rate of CD+34 in relapsed/refractory group (66.7 %) was higher than that in de novo group (32.6 %)(P 0.05). Positive rate of P-gp function in relapsed/refractory group (66.7 %) was higher than that in de novo group (25.6 %) (P 0.01). Conclusion CD34 expression has positive relevance with P-gp expression and function. Positive rate of CD34 and P-gp function in relapsed/refractory group are higher than those in De novo AML group. Monitoring P-gp function is more significant in clinical application.

About this research paper

What this paper is about

Objective To study the expression and function of P-glycoprotein in patients of relapsed/refractory acute myelogenous leukemia(AML). Methods CD34 expression was detected by immunohistochemistry, P-gp expression was detected by RT-PCR and P-gp function was analyzed by flow cytometry. Results CD34 expression has positive relevance with P-gp expression and function(r =0.621, P 0.001; r =0.496, P 0.001). P-gp expression has positive relevance with P-gp function (r = 0.574, P 0.01); positive rate of CD+34 in relapsed/refractory group (66.7 %) was higher than that in de novo group (32.6 %)(P 0.05). Positive rate of P-gp function in relapsed/refractory group (66.7 %) was higher than that in de novo group (25.6 %) (P 0.01). Conclusion CD34 expression has positive relevance with P-gp expression and function. Positive rate of CD34 and P-gp function in relapsed/refractory group are higher than those in De novo AML group. Monitoring P-gp function is more significant in clinical application.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To study the expression and function of P-glycoprotein in patients of relapsed/refractory acute myelogenous leukemia(AML). Methods CD34 expression was detected by immunohistochemistry, P-gp expression was detected by RT-PCR and P-gp function was analyzed by flow cytometry. Results CD34 expression has positive relevance with P-gp expression and function(r =0.621, P 0.001; r =0.496, P 0.001). P-gp expression has positive relevance with P-gp function (r = 0.574, P 0.01); positive rate of CD+34 in relapsed/refractory group (66.7 %) was higher than that in de novo group (32.6 %)(P 0.05). Positive rate of P-gp function in relapsed/refractory group (66.7 %) was higher than that in de novo group (25.6 %) (P 0.01). Conclusion CD34 expression has positive relevance with P-gp expression and function. Positive rate of CD34 and P-gp function in relapsed/refractory group are higher than those in De novo AML group. Monitoring P-gp function is more significant in clinical application.

Key concepts: P-glycoprotein, CD34, Clinical significance, Refractory (planetary science), Flow cytometry, Leukemia, Internal medicine, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Analyses of expression and function of P-glycoprotein in relapsed/refractory acute myelogenous leukemia patients — Research Paper | ScholarLens